The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RCKT as a result. In 61 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.725) is normal, around the industry mean (2.788). P/E Ratio (-15.219) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TECH saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 59 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Following a +0.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 190 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 94 of 231 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 60 cases where TECH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
TECH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.405) is normal, around the industry mean (2.788). P/E Ratio (62.103) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (133.911) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 74 | |
PRICE GROWTH RATING 1..100 | 72 | 27 | |
P/E GROWTH RATING 1..100 | 15 | 89 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (10) in the Biotechnology industry is significantly better than the same rating for TECH (93). This means that RCKT’s stock grew significantly faster than TECH’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as TECH (100). This means that RCKT’s stock grew similarly to TECH’s over the last 12 months.
TECH's SMR Rating (74) in the Biotechnology industry is in the same range as RCKT (92). This means that TECH’s stock grew similarly to RCKT’s over the last 12 months.
TECH's Price Growth Rating (27) in the Biotechnology industry is somewhat better than the same rating for RCKT (72). This means that TECH’s stock grew somewhat faster than RCKT’s over the last 12 months.
RCKT's P/E Growth Rating (15) in the Biotechnology industry is significantly better than the same rating for TECH (89). This means that RCKT’s stock grew significantly faster than TECH’s over the last 12 months.
| RCKT | TECH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 86% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 55% |
| Advances ODDS (%) | 3 days ago 80% | 9 days ago 66% |
| Declines ODDS (%) | 8 days ago 87% | 15 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 41% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RCKT’s FA Score shows that 2 FA rating(s) are green while TECH’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RCKT’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 3 bullish TA indicator(s).
RCKT (@Biotechnology) experienced а -4.13% price change this week, while TECH (@Biotechnology) price change was -0.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.38%. For the same industry, the average monthly price growth was -4.81%, and the average quarterly price growth was -15.79%.
RCKT is expected to report earnings on Mar 01, 2027.
TECH is expected to report earnings on Feb 02, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HBR | 9.57 | N/A | N/A |
| CANARY CAPITAL GROUP | |||
| DHY | 16.59 | -0.21 | -1.25% |
| UBS Asset Management High Yield Credit Fund | |||
| ESGD | 101.93 | -3.08 | -2.93% |
| iShares ESG Aware MSCI EAFE ETF (ESGD) | |||
| HFEQ | 21.96 | -0.97 | -4.25% |
| Unlimited HFEQ Equity Long/Short ETF (HFEQ) | |||
| QJUN | 31.24 | -1.48 | -4.52% |
| FT Vest Nasdaq-100 Buffer ETF - June (QJUN) | |||